KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Raw Materials: 2012-2022

Historic Raw Materials for TherapeuticsMD (TXMD) over the last 4 years, with Sep 2022 value amounting to $1.9 million.

  • TherapeuticsMD's Raw Materials fell 44.19% to $1.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.9 million, marking a year-over-year decrease of 44.19%. This contributed to the annual value of $3.0 million for FY2021, which is 18.84% down from last year.
  • As of Q3 2022, TherapeuticsMD's Raw Materials stood at $1.9 million, which was up 348.39% from $434,000 recorded in Q2 2022.
  • In the past 5 years, TherapeuticsMD's Raw Materials registered a high of $5.7 million during Q4 2019, and its lowest value of $19,400 during Q4 2018.
  • Over the past 3 years, TherapeuticsMD's median Raw Materials value was $3.6 million (recorded in 2020), while the average stood at $3.3 million.
  • As far as peak fluctuations go, TherapeuticsMD's Raw Materials soared by 29,290.45% in 2019, and later plummeted by 90.43% in 2022.
  • Over the past 5 years, TherapeuticsMD's Raw Materials (Quarterly) stood at $19,400 in 2018, then surged by 29,290.45% to $5.7 million in 2019, then crashed by 34.27% to $3.7 million in 2020, then decreased by 18.84% to $3.0 million in 2021, then plummeted by 44.19% to $1.9 million in 2022.
  • Its Raw Materials was $1.9 million in Q3 2022, compared to $434,000 in Q2 2022 and $4.4 million in Q1 2022.